<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566800</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000576425</org_study_id>
    <secondary_id>VAMCK-JB0027</secondary_id>
    <secondary_id>GENENTECH-OSI3717s</secondary_id>
    <nct_id>NCT00566800</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Barrett Esophagus</brief_title>
  <official_title>Chemoprevention Trial Using Erlotinib in Barrett's Esophagus With High-Grade Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib&#xD;
      may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some&#xD;
      of the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with&#xD;
      Barrett esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine if erlotinib hydrochloride can be used as a chemopreventive agent that can&#xD;
           cause histologic regression of Barrett esophagus in patients at high risk of developing&#xD;
           esophageal cancer associated with high-grade dysplasia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess whether erlotinib hydrochloride can cause molecular alterations in EGFR,&#xD;
           phospho-EGFR, cyclin D1, cdc2, p16, p53, PCNA, COX-2, and ploidy in Barrett esophagus&#xD;
           with high-grade dysplasia.&#xD;
&#xD;
        -  To establish surrogate markers of chemoprevention in Barrett esophagus with high-grade&#xD;
           dysplasia.&#xD;
&#xD;
        -  To validate the histologic scoring of Barrett dysplasia developed by our group.&#xD;
&#xD;
        -  To evaluate toxicities associated with the use of erlotinib hydrochloride in patients&#xD;
           with Barrett esophagus associated with high-grade dysplasia.&#xD;
&#xD;
      OUTLINE: Patients receive oral erlotinib hydrochloride once daily for 3 months. Patients&#xD;
      showing no evidence of progression to cancer by esophagogastroduodenoscopy (EGD) with biopsy&#xD;
      receive an additional 3 months of treatment. All patients then undergo repeat EGD, biopsy,&#xD;
      and determination of molecular markers (i.e., EGFR, phospho-EGFR, cyclin D1, cdc2, p16, p53,&#xD;
      PCNA, COX-2, and ploidy).&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular alterations in EGFR, phospho-EGFR, cyclin D1, cdc2, p16, p53, PCNA, COX-2, and ploidy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of histologic scoring of Barrett dysplasia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of Barrett esophagus with high-grade dysplasia&#xD;
&#xD;
          -  Refused surgery or other localized therapy for high-grade dysplasia&#xD;
&#xD;
          -  No invasive esophageal carcinoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 3 times ULN&#xD;
&#xD;
          -  No uncontrolled medical condition&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 1 week after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Able to swallow tablets or dissolved tablets&#xD;
&#xD;
          -  No known hypersensitivity to erlotinib hydrochloride&#xD;
&#xD;
          -  No symptoms suggestive of malignancy (e.g., weight loss or vomiting)&#xD;
&#xD;
          -  No history of other malignancies&#xD;
&#xD;
          -  No uncontrolled medical or psychiatric condition that would preclude treatment under&#xD;
             this clinical trial&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior exposure to erlotinib hydrochloride&#xD;
&#xD;
          -  No concurrent antineoplastic or antitumor agents, including chemotherapy,&#xD;
             radiotherapy, immunotherapy, or hormonal therapy&#xD;
&#xD;
          -  No concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquina C. Baranda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City Veteran Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquina C. Baranda, MD</last_name>
      <phone>816-861-4700 ext 6708</phone>
      <email>joaquina.baranda2@med.va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>December 1, 2007</study_first_submitted>
  <study_first_submitted_qc>December 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>esophageal cancer</keyword>
  <keyword>Barrett esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

